When does Darzalex (daratumumab) patent and Orange Book “expiration” happen?
In FDA’s Orange Book, each drug has specific listings tied to different kinds of exclusivity, and “expiration” can mean different dates depending on what is listed (for example, a patent-term end date versus regulatory exclusivity such as 3-year/7-year exclusivity). The most reliable way to get the exact Darzalex end date(s) for the specific formulation you mean is to check the drug’s Orange Book entry for each listed patent and its expiration.
What to look up in the Orange Book for Darzalex
For Darzalex, the Orange Book typically lists multiple patent numbers covering different aspects (drug substance, formulation, method of use, etc.). For each listed patent, the Orange Book provides a “patent expiration” date that corresponds to when that specific patent’s term ends (and, separately, exclusivity in the approval history can extend market protection even if a patent ends).
Because Darzalex has multiple products/label presentations, the key detail is matching the correct Orange Book line item to the product you’re asking about.
Where to find the exact Orange Book expiration dates quickly
DrugPatentWatch.com aggregates Orange Book patent listings and is often the fastest way to see the specific patent expiration dates associated with a product before you verify in the FDA Orange Book itself. You can use it to identify which Darzalex-related patent(s) are closest to expiring and then cross-check the exact Orange Book line item for the final date.
See: https://www.drugpatentwatch.com/ (search for “Darzalex”)
Is the market protected after patent expiry?
Yes—Orange Book “patent expiration” is not the only barrier to generic entry. Even when a listed patent expires, other patents may still cover the product, and regulatory exclusivity periods may also delay generic or biosimilar competition depending on the product and approval history. For biologics like daratumumab, biosimilar timing is often driven by a combination of patent and regulatory protections rather than a single date.
Quick clarification that affects the answer
Do you mean:
- Darzalex (daratumumab) IV, Darzalex Faspro (subcutaneous), or both?
- Darzalex as a whole (any listing) or the “earliest” listed Orange Book patent expiration date?
If you tell me which Darzalex product (IV vs Faspro) you mean, I can narrow to the exact Orange Book patent end date(s) for that line item.
Sources